Ç×ü Ž»ö ½ÃÀå - ¼­ºñ½º¿Í Ç÷§Æû : ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø(-2035³â) - Ç×ü Ž»ö ½ºÅܺ°, ¹æ¹ýº°, ¼ºÁúº°, Ç×ü À¯Çüº°, Ä¡·á ¿µ¿ªº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Antibody Discovery Market - Focus on Services and Platforms: Industry Trends and Global Forecasts, till 2035 - Distribution by Antibody Discovery Step, Method, Nature of, Type of Antibody, Therapeutic Area, End-user and Geographical Regions
»óǰÄÚµå : 1821507
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 607 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,800,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 9,918,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 15,019,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 25,506,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Ç×ü Ž»ö ½ÃÀå : °³¿ä

Ç×ü Ž»ö ½ÃÀå ±Ô¸ð´Â ÇöÀç 24¾ï ´Þ·¯¿¡¼­ 2035³â±îÁö 66¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 10.5%ÀÇ ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ½ÃÀå ¼¼ºÐÈ­¿¡¼­´Â ½ÃÀå ±Ô¸ð¿Í ±âȸ¸¦ ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö·Î ±¸ºÐÇÕ´Ï´Ù.

Ç×ü Ž»ö ´Ü°è

Ç×ü Ž»ö ¹æ¹ý

Ç×üÀÇ ¼ºÁú

Ä¡·á ¿µ¿ª

Ç×ü À¯Çü

ÃÖÁ¾ »ç¿ëÀÚ

Áö¿ª

Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå ¼ºÀå ¹× µ¿Çâ

Ç×ü´Â À̹°ÁúÀÇ ½Äº°°ú ÁßÈ­¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ³ôÀº ƯÀ̼º°ú ¿ì¼öÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ µî ¸î °¡Áö À¯ÀÍÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ ÀÌ ºÐÀÚµéÀº ƯÈ÷ ¾Ï, ÀÚ°¡¸é¿ªÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ Ä¡·á¿¡¼­ À¯¸ÁÇÑ ´ë¾ÈÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÇöÀç Ç×ü´Â »ý¹°ÇÐÀû Á¦Á¦ Áß °¡Àå Å« ºÐ·ù¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÇöÀç±îÁö 80°³ ÀÌ»óÀÇ ºÐÀÚ°¡ ½ÂÀεǾú°í, 200°³ ÀÌ»óÀÇ ºÐÀÚ°¡ ÀüÀÓ»ó/Ž»ö ´Ü°è¿¡ ÀÖ´Ù´Â Á¡Àº ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù.

¿©·¯ Â÷·ÊÀÇ ½ÂÀο¡µµ ºÒ±¸Çϰí, ¼³°è, Á¦Á¶, ÀÓ»ó Àû¿ëÀÇ ¿©·¯ ´Ü°è¿¡ °ÉÃÄ ÀÌ ºÐ¾ßÀÇ ´Ù¾çÇÑ °úÁ¦´Â ¿©ÀüÈ÷ ÇØ°áµÇÁö ¾ÊÀº ä·Î ³²¾Æ ÀÖ½À´Ï´Ù. µû¶ó¼­ Çö´ë ÀǾàǰ °³¹ßÀÇ º¹À⼺À» °í·ÁÇÒ ¶§ ¿¬±¸ ³ë·ÂÀ» ÃÖÀûÈ­ÇÏ´Â Àü·«Àû ¼Ö·ç¼ÇÀ¸·Î ¾Æ¿ô¼Ò½ÌÀ» ¼±È£ÇÏ´Â ±â¾÷µµ ÀûÁö ¾Ê½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­°¡ ¿¹»óµÇ´Â ¹è°æ¿¡´Â ŸÀÓ¶óÀÎ ´ÜÃà, ½ÃÇè ½ÇÆÐ¿¡ µû¸¥ ÀçÁ¤Àû À§Çè °¨¼Ò, ¿öÅ©Ç÷οìÀÇ ½Å¼ÓÈ­ µî ´Ù¾çÇÑ ÀÌÀ¯°¡ ÀÖ½À´Ï´Ù. ÇöÀç ¾à 125°³ ±â¾÷ÀÌ ´Ù¾çÇÑ Ç×ü Ž»ö ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù.

ÀÌ ºÐ¾ß¿¡¼­´Â ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÇ ¹ßÀüÀÌ Áß¿äÇϸç, Ç×ü-Ç׿ø »óÈ£ÀÛ¿ëÀÇ ¿¹ÃøÀ» ¿ëÀÌÇÏ°Ô Çϰí, ¸®µå È­ÇÕ¹°ÀÇ ½Äº° È¿À²À» ³ôÀÏ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÀÌ·¯ÇÑ ¹ßÀü¿¡ ÈûÀÔ¾î Ç×ü Ž»ö ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ ºÐ¾ß¿¡¼­ Áö¼ÓÀûÀ¸·Î Çõ½ÅÀ» ÃßÁøÇØ ¿Â ¿©·¯ ÀÌÇØ°ü°èÀڵ鿡°Ô ÀÌÀÍÀ» °¡Á®´Ù ÁÙ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ º¸°í¼­´Â Ç×ü Ž»ö ½ÃÀåÀÇ ÇöȲÀ» Á¶»çÇÏ°í ¾÷°è ³» ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù. º» º¸°í¼­ÀÇ ÁÖ¿ä Á¶»ç °á°ú´Â ´ÙÀ½°ú °°½À´Ï´Ù.

Antibody Discovery Market-IMG1
Antibody Discovery Market-IMG2
Antibody Discovery Market-IMG3

Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå ÁÖ¿ä ºÎ¹®

Ç×ü Ž»ö ´Ü°è¿¡ µû¶ó Ç×ü Ž»ö ½ÃÀåÀÇ ¼­ºñ½º ºÎ¹®Àº ¸®µå ÃÖÀûÈ­, ¸®µå ¼±ÅÃ, È÷Æ® âÃâ·Î ³ª´¹´Ï´Ù. ÇöÀç ¸®µå ÃÖÀûÈ­ ÇÏÀ§ ºÎ¹®ÀÌ Àüü ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐ(61%)À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¸®µå ÃÖÀûÈ­¸¦ ÅëÇØ ģȭ·Â, ¾ÈÁ¤¼º, ƯÀ̼º Ãø¸é¿¡¼­ °íǰÁúÀÇ Ç×ü Èĺ¸¹°ÁúÀÌ ¼±ÅõǾî ÀÓ»ó ¼º°ø °¡´É¼ºÀÌ ³ô¾ÆÁø´Ù´Â Á¡Àº ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù.

Ç×ü Ž»ö ¼­ºñ½º ½ÃÀåÀº Ž»ö ±â¹ý¿¡ µû¶ó ÇÏÀ̺긮µµ¸¶ ±â¹Ý ±â¹ý, ÆÄÁö µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¹Ý ±â¹ý, ÇüÁúÀüȯ µ¿¹° ±â¹Ý ±â¹ý, È¿¸ð µð½ºÇ÷¹ÀÌ ±â¹Ý ±â¹ý, ´ÜÀÏ ¼¼Æ÷ ±â¹Ý ±â¹ý, ±âŸ ±â¹ýÀ¸·Î ºÐ·ùµË´Ï´Ù.

ÇöÀç, ÇÏÀ̺긮µå µµ¸¶ ±â¹Ý ¹æ¹ýÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Ù(35%). ÇÏÀ̺긮µµ¸¶ ±â¹Ý ¹æ¹ýÀº È¿À²ÀûÀÌ°í º¹À⼺ÀÌ ³·±â ¶§¹®¿¡ Ç×ü Ž»öÀ» À§ÇÑ Ç×ü Ž»ö¿¡ ´ëÇÑ ÀαⰡ ³ô¾ÆÁö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ÇÏÀ̺긮µµ¸¶ ±â¹Ý ¹æ¹ýÀº ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ µîÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â Ä¡·á¿ë ´ÜÀÏŬ·ÐÇ×ü °³¹ß¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

Ç×üÀÇ ¼ºÁú¿¡ µû¶ó Ç×ü Ž»ö ½ÃÀåÀÇ ¼­ºñ½º ºÎ¹®Àº Àΰ£ Ç×ü, Àΰ£È­ Ç×ü, Ű¸Þ¶ó Ç×ü, ¸¶¿ì½º Ç×ü·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ¼¼°è ¼­ºñ½º ½ÃÀå¿¡¼­ Àΰ£ Ç×ü ÇÏÀ§ ºÎ¹®ÀÌ °¡Àå ³ôÀº Á¡À¯À²(53%)À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¸é¿ª¿ø¼º °¨¼Ò, Àΰ£¿¡¼­ ´ÜŬ·Ð Ç×üÀÇ Ç÷û ³» ¹Ý°¨±â ¿¬Àå µî Àΰ£ Ç×ü¿Í °ü·ÃµÈ ¸î °¡Áö ÀÌÁ¡ÀÌ ³ôÀº ½ÃÀå Á¡À¯À²¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Ç×ü Ž»ö ½ÃÀåÀÇ ¼­ºñ½º ºÐ¾ß ¼¼°è ½ÃÀå ±Ô¸ð´Â Ä¡·á ºÐ¾ßº°·Î ¾ÏÁúȯ, ¸é¿ªÁúȯ, °¨¿°Áúȯ, ½ÉÇ÷°üÁúȯ, ½Å°æÁúȯ, ±âŸ ÁúȯÀ¸·Î ±¸ºÐµË´Ï´Ù. ÇöÀç, ½ÃÀåÀº ¾Ï Áúȯ ÇÏÀ§ ºÎ¹®(48%)ÀÌ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î Á¾¾ç¼º ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡ Ãß¼¼¿¡ ÀÖ°í, Ç×ü ±â¹Ý Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ È¿°úÀûÀÎ Ä¡·áÁ¦ÀÇ °³¹ß ¹× »ý»êÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù.

Ç×ü À¯Çüº°·Î Ç×ü Ž»ö ½ÃÀåÀÇ ¼¼°è ¼­ºñ½º ºÎ¹®Àº ´ÜŬ·Ð Ç×ü, ÀÌÁß Æ¯À̼º Ç×ü, ¸é¿ª º¹ÇÕü µîÀ¸·Î ±¸ºÐµË´Ï´Ù. ÇöÀç, ½ÃÀåÀº ´ÜÀÏŬ·ÐÇ×ü(60%)°¡ Áö¹èÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ãß¼¼´Â ¾ÕÀ¸·Îµµ º¯ÇÏÁö ¾ÊÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ´Â ´ÜÀÏŬ·ÐÇ×ü°¡ ³ôÀº ƯÀ̼º, Àϰü¼º, ÀçÇö¼ºÀ» °¡Áö°í ÀÖ¾î Ç¥ÀûÄ¡·á¿¡ ÀÌ»óÀûÀ̱⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, mAbs´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ ³ôÀº È¿°ú¸¦ º¸ÀÌ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù.

¸¶Âù°¡Áö·Î, Ç×ü À¯Çü¿¡ µû¶ó ¼¼°è ±â¼ú ¹× Ç÷§Æû ½ÃÀåÀº ´ÜÀÏŬ·ÐÇ×ü, ÀÌÁß Æ¯À̼º Ç×ü, Ç×ü-¾à¹° º¹ÇÕü, ±âŸ Ç×ü µîÀ¸·Î ±¸ºÐµË´Ï´Ù.

±â¼ú ¹× Ç÷§Æû ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÎ¹®À¸·Î ºÎ»óÇÒ °Í

ÃÖÁ¾ »ç¿ëÀÚº°·Î Ç×ü Ž»ö ½ÃÀåÀÇ ±â¼ú ¹× Ç÷§Æû ½ÃÀåÀº ÀÎÇϿ콺 ±â¾÷¿Í °³¹ß ¾÷¹« À§Å¹ ±â°üÀ̶ó´Â ¼­·Î ´Ù¸¥ ÃÖÁ¾ »ç¿ëÀÚ·Î ±¸ºÐµË´Ï´Ù. ÀÎÇϿ콺 Á¦Á¶¾÷üÀÇ ÇÏÀ§ ºÎ¹®(98%)°¡ °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÎÇϿ콺 ±â¾÷ÀÌ Àü¹® ÆÀ°ú dzºÎÇÑ »ç³» ÀÚ¿øÀ» º¸À¯Çϰí ÁöÀû Àç»êÀ» °ü¸®Çϰí Àֱ⠶§¹®¿¡ ½Å¾à °³¹ß ÇÁ·Î¼¼½ºÀÇ È¿À²¼º°ú °æÀï ¿ìÀ§¸¦ À¯ÁöÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.

ÀÌ ºÎ¹®¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ºÏ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä« µî Áö¿ªº° ¼¼°è ¼­ºñ½º ½ÃÀå ±Ô¸ð ºÐÆ÷¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ç»çÀÇ ÃßÁ¤¿¡ µû¸£¸é, ÁÖ¿ä Á¦¾à»çÀÇ Á¸Àç, È®¸³µÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ´Ù¾çÇÑ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ¿ÃÇØ ºÏ¹Ì°¡ 50%ÀÇ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È 13.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î °ßÁ¶ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸¶Âù°¡Áö·Î, ±â¼ú ¹× Ç÷§Æû ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç µî ´Ù¾çÇÑ Áö¿ªÀ¸·Î ºÐ·ùµË´Ï´Ù. ºÏ¹Ì¿¡ º»»ç¸¦ µÐ ±â¼ú ¹× Ç÷§Æû Á¦°ø¾÷ü°¡ ü°áÇÑ ±â¼ú ¶óÀ̼±½º/ÅëÇÕ °è¾àÀÌ °¡Àå ¸¹±â ¶§¹®¿¡ ºÏ¹Ì°¡ Àüü ½ÃÀåÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÇâÈÄ ´õ ºü¸¥ ¼Óµµ(CAGR 9.30%)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

1Â÷ Á¶»ç °³¿ä

º» Á¶»ç¿¡¼­ Á¦½ÃµÈ Àǰ߰ú ÀλçÀÌÆ®·ÂÀº ½ÃÀåÀÇ ¿©·¯ ÀÌÇØ°ü°èÀÚ¿ÍÀÇ ³íÀǸ¦ ÅëÇØ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ, º» Á¶»ç º¸°í¼­¿¡´Â ¾÷°è ÀÌÇØ°ü°èÀÚµé°úÀÇ ÀÎÅÍºä ±â·ÏÀÌ »ó¼¼ÇÏ°Ô ¼ö·ÏµÇ¾î ÀÖ´Ù(¿¬°ø¼­¿­).

Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå ÁøÃâ±â¾÷ »ç·Ê

Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå Á¶»ç ´ë»ó

¸ñÂ÷

¼½¼Ç I : º¸°í¼­ °³¿ä

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ½ÃÀå ¿ªÇÐ

Á¦4Àå °Å½Ã°æÁ¦ ÁöÇ¥

¼½¼Ç II : Á¤¼ºÀû ÀλçÀÌÆ®

Á¦5Àå ÁÖ¿ä ¿ä¾à

Á¦6Àå ¼­·Ð

Á¦7Àå Ç×ü Ž»ö : ÇÁ·Î¼¼½º¿Í ¹æ¹ý

¼½¼Ç III : °æÀï ±¸µµ

Á¦8Àå ½ÃÀå ±¸µµ : Ç×ü Ž»ö ¼­ºñ½º Á¦°ø¾÷ü

Á¦9Àå ½ÃÀå ±¸µµ : Ç×ü Ž»ö ±â¼ú ¹× Ç÷§Æû

Á¦10Àå ±â¾÷ °æÀï·Â ºÐ¼®

Á¦11Àå ±â¼ú °æÀï·Â ºÐ¼®

¼½¼Ç IV : ±â¾÷ °³¿ä

Á¦12Àå Ç×ü Ž»ö ¼­ºñ½º Á¦°ø¾÷ü : ºÏ¹Ì¿¡ °ÅÁ¡À» µÐ ±â¾÷ °³¿ä

Á¦13Àå Ç×ü Ž»ö ¼­ºñ½º Á¦°ø¾÷ü : À¯·´¿¡ °ÅÁ¡À» µÐ ±â¾÷ °³¿ä

Á¦14Àå Ç×ü Ž»ö ¼­ºñ½º Á¦°ø¾÷ü : ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡ °ÅÁ¡À» µÐ ±â¾÷ °³¿ä

Á¦15Àå Ç×ü Ž»ö ±â¼ú ¹× Ç÷§Æû ÇÁ·Î¹ÙÀÌ´õ : ºÏ¹Ì¿¡ °ÅÁ¡À» µÐ ±â¾÷ °³¿ä

Á¦16Àå Ç×ü Ž»ö ±â¼ú ¹× Ç÷§Æû ÇÁ·Î¹ÙÀÌ´õ : À¯·´¿¡ °ÅÁ¡À» µÐ ±â¾÷ °³¿ä

¼½¼Ç V : ½ÃÀå µ¿Çâ

Á¦17Àå ÆÄÆ®³Ê½Ê ¹× Çù¾÷

Á¦18Àå ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ ºÐ¼®

¼½¼Ç VI : ½ÃÀå ±âȸ ºÐ¼®

Á¦19Àå ½ÃÀå ¿µÇ⠺м® : ¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎ, ±âȸ, °úÁ¦

Á¦20Àå ¼¼°èÀÇ Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå

Á¦21Àå Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå(Ç×ü Ž»ö ½ºÅܺ°)

Á¦22Àå Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå(Ç×ü Ž»ö ¹æ¹ýº°)

Á¦23Àå Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå(Ç×ü ¼ºÁúº°)

Á¦24Àå Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå(Ä¡·á ¿µ¿ªº°)

Á¦25Àå Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå(Ç×ü À¯Çüº°)

Á¦26Àå Ç×ü Ž»ö ¼­ºñ½º ½ÃÀå(Áö¿ªº°)

Á¦27Àå ¼¼°èÀÇ Ç×ü Ž»ö ±â¼ú ¹× Ç÷§Æû ½ÃÀå

Á¦28Àå Ç×ü Ž»ö ±â¼ú ¹× Ç÷§Æû ½ÃÀå(Ç×ü À¯Çüº°)

Á¦29Àå Ç×ü Ž»ö ±â¼ú ¹× Ç÷§Æû ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦30Àå Ç×ü Ž»ö ±â¼ú ¹× Ç÷§Æû ½ÃÀå(Áö¿ªº°)

Á¦31Àå ¶óÀ̼±½Ì °è¾à ±¸Á¶

Á¦32Àå »ç·Ê : È÷Æ® »óǰ Ç×ü Drug Discovery ÇÁ·Î¼¼½º

Á¦33Àå Ç×ü Ž»öÀÇ ÇâÈÄ ¼ºÀå ±âȸ

¼½¼Ç VII : ±âŸ µ¶Á¡Àû ÀλçÀÌÆ®

Á¦34Àå °á·Ð

Á¦35Àå °æ¿µÁø ÀλçÀÌÆ®

¼½¼Ç VIII : ºÎ·Ï

Á¦36Àå ºÎ·Ï I : Ç¥ µ¥ÀÌÅÍ

Á¦37Àå ºÎ·Ï II : ±â¾÷ ¹× Á¶Á÷ ¸®½ºÆ®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Antibody Discovery Market: Overview

As per Roots Analysis, the antibody discovery market is estimated to grow from USD 2.4 billion in the current year to USD 6.6 billion by 2035, representing a higher CAGR of 10.5% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Antibody Discovery Step

Antibody Discovery Method

Nature of Antibody

Therapeutic Area

Type of Antibody

End-user

Geographical Regions

Antibody Discovery Services Market: Growth and Trends

Antibodies play a pivotal role in the identification and neutralization of foreign substances. Owing to several beneficial features, such as high specificity, and a favorable safety profile, these molecules have emerged as a promising alternative, particularly for the treatment of cancer, autoimmune diseases, and infectious diseases. It is worth highlighting that, at present, antibodies represent the largest class of biologics, with over 80 molecules approved till date and over 200 molecules in the preclinical / discovery stages.

Despite multiple approvals, various challenges in the domain remain unaddressed across several stages of design, production, and clinical application. Therefore, given the complexities of modern drug development, several companies prefer to outsource as a strategic solution to optimize their research efforts. This expected shift can be attributed to various reasons, such as reduced timelines, lessened financial risks associated with failed trials and accelerated workflows. At present, around 125 players are offering a wide array of antibody discovery services.

This field possesses significant promise for future breakthroughs, wherein advances in artificial intelligence and machine learning is expected to be crucial, facilitating the prediction of antibody-antigen interactions and enhancing the efficiency of lead identification.

Fueled by these developments, the antibody discovery market is expected to progress in the coming years, benefiting multiple stakeholders who have consistently fostered innovation in this field

Antibody discovery market: Key Insights

The report delves into the current state of the antibody discovery market and identifies potential growth opportunities within industry. Some key findings from the report include:

Antibody Discovery Market - IMG1
Antibody Discovery Market - IMG2
Antibody Discovery Market - IMG3

Antibody Discovery Services Market: Key Segments

Lead Optimization Segment Captures that Majority of the Market Share

Based on the antibody discovery step, the services segment of antibody discovery market is distributed across lead optimization, lead selection and hit generation. Currently, the lead optimization sub-segment occupies the majority (61%) of the share in the overall market. It is worth highlighting that lead optimization ensures the selection of high-quality antibody candidates in terms of affinity, stability, and specificity, thereby increasing their likelihood of clinical success.

Antibody Discovery Services Segment is leading the Antibody Discovery Market

Based on the discovery method, the services segment of antibody discovery market is segmented into hybridoma-based methods, phage display library-based methods, transgenic animal-based methods, yeast display-based methods, single cell-based methods and other methods.

Presently, the market is dominated by hybridoma-based methods (35%) since the popularity of hybridoma-based methods for the discovery of antibodies has risen, owing to its efficiency and low complexity. Moreover, hybridoma-based methods have been crucial in developing therapeutic monoclonal antibodies used in treatment of diseases, including cancer, autoimmune disorders, and infections.

Based on Nature of Antibody, Human Antibodies Sub-Segment Occupies the Highest Share

Based on the nature of antibody, the services segment of antibody discovery market is segmented into human antibodies, humanized antibodies, chimeric antibodies and murine antibodies. The human antibodies sub-segment occupies the highest share (53%) in the current global services market. Several benefits associated with human antibodies, including reduced immunogenicity and the increased serum half-life of the monoclonal antibodies in humans, contribute to the high market share.

Oncological Disorders Dominate the Current Antibody Discovery Market

The global market value for services segment of antibody discovery market, based on different therapeutic areas, is segmented into oncological disorders, immunological disorders, infectious diseases, cardiovascular disorders, neurological disorders and other disorders. Currently, the market is dominated by oncological disorders sub-segment (48%). This can be attributed to the fact that incidence of oncological disorders has been on the rise globally, necessitating the development and production of effective treatments, including antibody-based therapeutics.

By Type of Antibody, Monoclonal Antibodies are Likely to Dominate the Market During the Forecast Period

Based on the type of antibody, the global services segment of antibody discovery market is segmented into monoclonal antibodies, bispecific antibodies and immunoconjugates. In the current year, the market is dominated by monoclonal antibodies (60%) and the trend is unlikely to change in the future as well. This can be attributed to the fact that monoclonal antibodies offer high specificity, consistency, and reproducibility, which makes them ideal for targeted therapies. In addition, mAbs have proven to be highly effective in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

Similarly, based on the type of antibody, the global technologies / platforms market is segmented into monoclonal antibodies, bispecific antibodies, antibody drug conjugates and other antibodies.

The Technologies / Platforms Market is the Fastest Growing Segment of the During the Forecast Period

In terms of end-user, the global technologies / platforms market segment of antibody discovery market is segmented across different end-users, namely in-house players and contract research organizations. In-house players' sub-segment (98%) occupies the highest market share. This can be attributed to the fact that in-house players mostly have dedicated teams, access to extensive in-house resources, and control over intellectual property, which enables them to streamline the discovery process and maintain competitive advantages.

North America Accounts for the Largest Share of the Market

This segment highlights the distribution of global services market size across geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Our estimates suggest that the majority share in the current year is captured by North America (50%) owing to the presence of big pharma players, well-established regulatory framework, and various technological advancements in this region. On the contrary, Asia-Pacific is poised for the healthy growth rate (with a CAGR of 13.3%) during the forecast period.

Likewise, technologies / platforms market is segmented across various geographies, including North America, Europe and Asia-Pacific. Our estimates suggest that, North America is likely to capture the majority of the overall market share driven by maximum number of technology licensing / integration deals inked by technology / platform providers headquartered in this region.

Further, the market in Asia-Pacific is anticipated to increase at a faster pace (CAGR of 9.30%) in the foreseen future.

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the industry stakeholders (arranged in decreasing order of seniority level):

Example Players in the Antibody Discovery Services Market

Antibody Discovery Services Market: Research Coverage

Key Questions Answered in this Report

Reasons to Buy this Report

Additional Benefits

TABLE OF CONTENTS

SECTION I: REPORT OVERVIEW

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. ANTIBODY DISCOVERY: PROCESSES AND METHODS

SECTION III: COMPETITIVE LANDSCAPE

8. MARKET LANDSCAPE: ANTIBODY DISCOVERY SERVICE PROVIDERS

9. MARKET LANDSCAPE: ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS

10. COMPANY COMPETITIVENESS ANALYSIS

11. TECHNOLOGY COMPETITIVENESS ANALYSIS

SECTION IV: COMPANY PROFILES

12. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

13. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

14. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC

15. ANTIBODY DISCOVERY TECHNOLOGY / PLATFORM PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

16. ANTIBODY DISCOVERY TECHNOLOGY / PLATFORM PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

SECTION V: MARKET TRENDS

17. PARTNERSHIPS AND COLLABORATIONS

18. FUNDING AND INVESTMENT ANALYSIS

SECTION VI: MARKET OPPORTUNITY ANALYSIS

19. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

20. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET

21. ANTIBODY DISCOVERY SERVICES MARKET, BY ANTIBODY DISCOVERY STEP

22. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD

23. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY

24. ANTIBODY DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

25. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY

26. ANTIBODY DISCOVERY SERVICES MARKET, BY GEOGRAPHICAL REGIONS

27. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET

28. ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET, BY TYPE OF ANTIBODY

29. ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET, BY TYPE OF END-USER

30. ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET, BY GEOGRAPHICAL REGIONS

31. LICENSING DEAL STRUCTURE

32. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

33. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

SECTION VII: OTHER EXCLUSIVE INSIGHTS

34. CONCLUDING INSIGHTS

35. EXECUTIVE INSIGHTS

SECTION VIII: APPENDICES

36. APPENDIX I: TABULATED DATA

37. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â